Why omeros Is Trending Today?

Omeros, a biopharmaceutical company, saw its stock surge by 149% following a $2 billion deal with Novo Nordisk to acquire Omeros' blood disease drug, zaltinibart. This significant agreement has placed Omeros in the spotlight of investors, alongside other notable companies such as Hims & Hers, Salesforce, United Airlines, and Sea Ltd. The market is speculating whether there is still room for Omeros' stock to continue its upward trend after this substantial deal. In an international development, Novo Nordisk, a Danish multinational pharmaceutical company, has purchased a rare blood disease medication from Omeros for up to $2.1 billion.